Latest Updates
-
Ahmedabad Police Flag Fraud Risk Behind Viral 'Rent A Garba Partner' Ads -
Vidya Balan’s Jailer 2 Entry As Kantha: From Silk To Manjulika, A Look At Her Unconventional Roles -
Samay Raina Has Now Denied Dating Rumours With Two Women In Three Months -
Kareena Kapoor Turns 46: From Size Zero To Fine Lines, The ‘Daayra’ Actress Is Choosing To Age Without Apology -
The Emotional Side of Delayed Parenthood That We Don’t Talk About Enough -
World Alzheimer’s Day 2026: Why Early Diagnosis Matters And What This Year’s Theme Means -
When Is Navratri In 2026? Full Dates, Rituals, Colours, Significance, and Fasting Guide -
Vijay Sethupathi Confirms Maharaja 2, Hollywood Remake In The Works -
Dashavatara Vrat 2026: Everything To Know About Tithi, Rituals, Fasting And The Ten Forms Of Lord Vishnu -
Senior Journalist Payal Mehta Passes Away At 46; PM Modi, Rahul Gandhi, Other Political Leaders Pay Tributes
Old Drug May Hold Promise Against Hepatitis C

Researchers from Stanford University say that an old drug may be effective against hepatitis C.
The research team say that their hunch is based on two significant discoveries in fight against hepatitis C:
A protein called NS4B is actively involved in binding some of the genetic material, or RNA, and thus allows the virus to duplicate.
An obsolete anti-itching drug clemizole hydrochloride could obstruct the protein, leading to a tenfold decrease in virus replication.
"We're excited about this and we're actively moving forward toward clinical trials," Nature magazine quoted Dr. Jeffrey Glenn, associate professor of gastroenterology and hepatology, as saying.
With the help of coin-sized microfluidic chips that minimizes tabletop biological experiments down to the tiny scale of nanoliters, the research team was able to screen more than 1,200 drug candidates and find clemizole in just two weeks.
Unlike other proteins, NS4B is difficult to purify in large quantities while retaining the protein's natural properties and functionality.
Stephen Quake, PhD, professor of bioengineering and the other senior author said that the paper marks the first time that microfluidic technology has been used to discover a specific drug.
While researching for the specific drug to target the protein, co author Doron Gerber, PhD, in bioengineering discovered18 drugs that substantially reduced NS4B binding to its target RNA.
However they focused on clemizole because it is already known to be safe in humans.
Glenn said, that clemizole could become an essential component in a new class of multidrug treatments for hepatitis C.
The study appears in online edition of the journal Nature Biotechnology.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications
